|
December 6, 2005 Categories: Blogroll Posted by admin
Indianapolis (Bloomberg News) — Johnson & Johnson’s planned $25.4 billion purchase of Indianapolis-based Guidant Corp. will get a four-month review from European Union regulators who want to examine whether the company would dominate the market for treatment of coronary and peripheral artery diseases and cardiac surgery.
Full news
|
|
